What’s New for Biologics | FDA

What’s New for Biologics | FDA

9/16/2019	Expanded Access to Experimental Biologics
9/13/2019	Select CBER Projects and Activities
9/12/2019	Influenza Vaccine for the 2019-2020 Season Update
9/10/2019	August 1, 2019 Summary Basis for Regulatory Action - 0.9% Sodium Chloride Injection USP
9/10/2019	September 5, 2019 Approval Letter - 0.9 % Sodium Chloride Injection USP
9/9/2019	FDA identifies biomarker for immune response to FVIII products used to treat hemophilia A
9/6/2019	August 27, 2019 Summary Basis for Regulatory Action - cobas Babesia
9/4/2019	Complete List of Currently Approved NDA and ANDA Application Submissions Updated as of 8/30/2019
9/4/2019	Complete List of Currently Approved Premarket Applications (PMAs) Updated as of 8/30/2019
9/4/2019	Complete List of Substantially Equivalent 510(k) Device Applications Updated as of 8/30/2019
9/4/2019	Complete List of Licensed Products and Establishments Updated as of 8/30/2019
9/3/2019	Novel machine learning technique identifies populations of stimulated mesenchymal stromal cells with immunosuppressive activity
8/30/2019	August 29, 2019 Approval Letter – cobas Babesia
8/30/2019	Identification and Use of Biomarkers to Advance Development of Preventive Vaccines-Agenda
8/29/2019	Exceptions and Alternative Procedures Approved Under 21 CFR 640.120 Update
8/29/2019	August 26, 2019 Summary Basis for Regulatory Action - Geenius HIV 1/2  Supplemental Assay
8/27/2019	Developing Alpha-1 Antitrypsin Therapeutics; Public Workshop - Agenda
8/27/2019	August 26, 2019 Approval Letter - Geenius HIV 1/2 Supplemental Assay
8/26/2019	CBER-Regulated Products: Resolved Shortages Information on Aplisol
8/26/2019	2019 Biological License Application Approvals Update
8/26/2019	2019 Biological License Application Supplement Noteworthy Approvals Update
8/26/2019	2019 Biological Device Application Approvals Update
8/22/2019	Perspectives on In Vitro Diagnostic Devices Regulated by the Office of Blood Research and Review/CBER; Public Workshop Transcript for July 15, 2019
8/22/2019	Perspectives on In Vitro Diagnostic Devices Regulated by the Office of Blood Research and Review/CBER; Public Workshop Transcript for July 16, 2019
8/22/2019	CBER-Regulated Products: Current Shortages Information on Imogam
8/22/2019	CBER-Regulated Products: Current Shortages Update on Gammaplex
8/20/2019	August 14, 2019 Summary Basis for Regulatory Action - Alinity s Chagas
8/16/2019	August 15, 2019 Approval Letter - Alinity s Chagas
8/16/2019	Summary Basis for Regulatory Action - Blood Grouping Reagent, Anti -A (Murine Monoclonal) (FFMU) STN 125669 & 125680
8/15/2019	CBER Vacancy: Senior Staff Fellow - Microbial Pathogenesis
8/15/2019	Developing Alpha-1 Antitrypsin Therapeutics; Public Workshop
8/13/2019	August 12, 2019 Approval Letter - Blood Grouping Reagent, Anti-A (Murine Monoclonal) STN# 125449/44
8/13/2019	August 12, 2019 Approval Letter - Blood Grouping Reagent, Anti-A (Murine Monoclonal) (FFMU) STN# 125669
8/13/2019	August 12, 2019 Approval Letter - Blood Grouping Reagent, Anti-A (Murine Monoclonal) (FFMU) STN# 125680
8/12/2019	Information About Immune Globulin (Human) Product Shortage
8/9/2019	Regulatory Harmonization and Convergence Update
8/9/2019	July 18, 2019 Summary Basis for Regulatory Action - Alinity s Anti-HBc
8/7/2019	Annual Summary for Fiscal Year 2018
8/6/2019	BK180301 - PK7400 TP HA Controls and PK7400 TP HA Reagent
8/5/2019	August 2, 2019 - Approval Letter Alinity s Anti-HBc